Preventing unintentional weight and muscle loss is of crucial importance to maintain the condition and wellbeing of patients with cancer, improve treatment response and tolerance, and prolong survival. Anabolic resistance might explain why some cancer patients do not respond to nutritional intervention, but does recent evidence actually support this? We will discuss recent literature that casts doubt on attenuated anabolic potential in cancer.
INTRODUCTION
Cachexia in cancer is a complex metabolic syndrome characterized by weight loss because of loss of muscle mass with or without loss of fat mass. Some form of cancer cachexia is commonly present in many cancer types [1 & ] and is known to negatively affect performance status [2] , the response and tolerance to therapy [3] , and survival [4,5 && ]. A spectrum of cachexia (precachexia, cachexia, and refractory cachexia) often evolves in the cancer trajectory, although not all patients will progress through the full spectrum. About half of all patients with cancer lose some body weight, and the prevalence and severity of weight loss varies greatly according to the tumor site and type 
MUSCLE WASTING, REDUCED PROTEIN INTAKE, AND DISTURBANCES IN PROTEIN METABOLISM IN CANCER
Despite the fact that the prevalence of cachexia has not changed considerably in the past decades [1 & ,6] , both the general population and the cancer population show the same trend in the increased prevalence of obesity ( Fig. 1) . This supports the notion that the overall nutritional condition of cancer patients has improved and that weight loss nowadays results in a shift from obese to overweight rather than from normal weight to underweight [7] [8] [9] . Also, the higher BMI in overweight and obese populations is significantly associated with higher values for muscle mass [10] . This most likely has an impact on the metabolic profile of weight-losing cancer patients.
Normal or even high values for body weight or fat mass were found in patients with nonsmall cell lung cancer (NSCLC) despite the presence of some skeletal muscle loss [11 & ,12,13] . This muscle loss, however, was not associated with muscle weakness. It probably matters whether weight loss in cancer takes place from an initial BMI of 30 or 20 kg/m 2 , as the changes in body composition (muscle and fat mass) might differ between both starting BMIs. Recent studies, however, show that low skeletal muscle mass is an independent adverse prognostic indicator in cancer whether or not combined with overweight or obesity [14, 15] .
To be able to explain the variation in muscle and fat loss among cancer patients, habitual protein intake and the underlying metabolic disturbances need to be assessed. 
KEY POINTS
With the obesity pandemic, cancer patients are likely to be normal or overweight, which may positively affect their metabolic profile and muscle mass, and reduce the negative effects of weight loss.
Advanced cancer patients are able to obtain a normal protein anabolic response to high-quality proteins (enteral or parenteral).
When the dose of high-quality proteins or amino acids in the diet increases, protein anabolism is stimulated in cancer patients.
Optimal protein and amino acid intake is critical in advanced cancer patients and needs to be determined to further improve and personalize their nutritional care.
The remaining anabolic capacity of very weak cancer patients with a short life expectancy and profound systemic inflammation needs to be established. cancer survivors, and patients with nonsmall cell lung cancer at presentation for cancer surgery [7] [8] [9] . Cancer survivors were defined as adults ever diagnosed with cancer (except for nonmelanoma skin cancer).
muscle protein metabolism, most of the data were obtained in animal models of cancer cachexia. Underlying disturbances in muscle protein metabolism in patients with cancer have been assessed by measuring the protein fractional synthesis rate of muscle proteins using stable isotope methodology in the postabsorptive state and in response to feeding as a proxy of anabolic capacity. In the postabsorptive condition, skeletal muscle protein fractional synthesis rate was found to be unchanged in cachectic cancer patients [21] . A recent study examining muscle myofibrillar protein synthesis over a period of 1-2 weeks found comparable values between healthy, weight-stable study participants, and weight-losing patients with upper gastrointestinal cancer [22] , suggesting that muscle wasting is likely more related to an increased muscle protein breakdown [21] . Furthermore, because of the invasive nature of taking muscle biopsies in cancer patients and the fact that muscle protein synthesis but not breakdown data could easily be obtained, recent studies started focusing more on measuring both protein synthesis and breakdown on whole body level. We recently found in patients with NSCLC with normal body weight and reduced leg muscle mass [11 & ] comparable values for postabsorptive whole body protein synthesis and breakdown rates as in the healthy control group. However, in cachectic pancreatic cancer patients, we found elevated values for whole body protein turnover [23] . It remains unclear whether muscle and whole body protein kinetics are uniformly modified among cancer patients.
IS THERE REALLY ANABOLIC RESISTANCE IN CANCER?
'Ongoing loss of skeletal muscle mass that cannot be reversed by conventional nutritional support' is an important part of the definition of cancer cachexia as stated by a panel of experts [24] . We previously confirmed that conventional nutritional supplementation using a commercially available formula is ineffective in stimulating muscle protein synthesis in advanced cancer patients (Table 1) [25] . A blunted response in muscle protein synthesis was also observed in colorectal cancer patients after infusion of a commercially available amino acid mixture [21] .
In the past 5 years, more studies have become available showing that cancer patients have an anabolic potential. An euglycemic, hyperinsulinemic clamp study in patients with stage III and IV NSCLC [13] revealed a normal anabolic response to hyperaminoacidemia but a blunted response to low levels of amino acids. This suggests that a substantial protein intake is required to induce protein anabolism in cancer which could be difficult when appetite is reduced. Our recent study in eight cachectic pancreatic cancer patients and seven controls receiving oral sip feeding of a commercially available complete meal [23] showed a comparable protein anabolic response in both groups, albeit through a different pattern of whole body protein kinetics. In the cachectic patients, the anabolic response was because of reduced protein breakdown, whereas in healthy controls, both a decrease in protein breakdown and an increase in protein synthesis were present. We showed in 13 advanced cancer patients (mainly lung and colorectal cancer) that a high-protein formula containing high leucine levels, specific oligosaccharides and fish oil, was able to stimulate muscle protein synthesis [25] . This suggests that the suppressed anabolic responsiveness to a conventional nutritional supplement in advanced cancer can be (at least partly) overcome by providing specially formulated nutrition. We recently confirmed this in a study in 13 patients with advanced NSCLC who did not show an anabolic resistance or attenuated anabolic potential in response to 14 g of either an essential amino acid mixture or a balanced amino acid mixture as present in whey protein [11 & ]. The high anabolic potential of free essential amino acids in the NSCLC patients was independent of their body weight, muscle mass, presence of recent weight loss, or disease trajectory. These studies show that diets with high levels of essential amino acids, either free or bound in protein, are anabolic in patients with cancer and healthy study participants.
The presence of anabolic resistance previously observed in some cancer studies but not in others could be related to multiple factors including characteristics of the study population (nutritional status, life expectancy, level of inflammation), dietary intake (protein dosage and amino acid composition), and the presence of anticancer treatment.
Nutritional status and life expectancy: it is possible that anabolic resistance to protein is more prevalent in patients with rapid or significant weight loss and muscle wasting. Although many studies reported a high prevalence of weight loss in cancer, the degree of weight loss differed depending on tumor type, tumor stage, anticancer treatment, and inflammatory state [1 ]. Data are needed whether this is also the case for the 3 months refractory period, but this study group is difficult to recruit. Some of the available studies might have unintentionally excluded these patients or these patients feel too weak to participate.
Inflammation: it has often been suggested that protein anabolism is extremely difficult to achieve in cancer in the presence of enhanced systemic inflammation as inflammation induces muscle proteolysis and reduces the sensitivity of skeletal muscle protein synthesis to amino acid supplementation. When reviewing the recent literature examining the acute anabolic response to a meal in cancer in the past years [11 & ,13,21,23,25] (Table 1) , average C-reactive protein, as marker of systemic inflammatory response, was mostly between 5 and 15 mg/l and independent of the cancer type and nutritional status. In colorectal cancer patients undergoing surgery, no relation was found between alterations in inflammatory mediators and the catabolic changes in protein turnover as the anabolic resistance disappeared 6 weeks after surgery [21] . It remains undetermined whether an attenuated anabolic response is more present in cancer patients with high levels of inflammation (i.e., C-reactive protein >50 mg/l).
Protein dosage and administration: Recent studies show that the dose of daily protein as well as the composition of the proteins and amino acids in a meal are among the most important factors influencing the anabolic response in cancer patients. Figure 2 shows a combined plot of the linear relationships between (essential) amino acid availability coming from the diet and net protein gain in normal weight NSCLC [11 & ] and cachectic pancreatic cancer with more than 10% recent weight loss [23] . The relationships between the amount of dietary essential amino acids and net protein anabolism were comparable between both cancer groups and the combined healthy control group, indicating that the anabolic response to feeding is dependent on the amount of essential amino acids in the diet, but independent of the presence of cancer, cancer type, or nutritional status. The linear relationship remained at higher protein and amino acid intakes suggesting that protein accretion is still present at intakes greater than the requirement level and that higher quantities of essential amino acids might be useful to these patients. In line, 40 g of Relation between intake and net protein anabolism FIGURE 2. Relationship between net protein anabolism and dietary essential amino acid intake in the healthy control (dark grey circles), nonsmall cell lung cancer (light grey triangles), and pancreatic cancer (black squares) groups (calculated with the essential amino acid phenylalanine) [11 amino acids incorporated in medical food [25] resulted in acute stimulation of muscle protein synthesis in advanced cancer. It is expected that when the dose of high-quality proteins or amino acids in the diet increases, protein anabolism will go up until factors like digestibility or absorption capacity starts to play a role. Currently, we do not know until what intake level this will occur. The previous critical appraisal of the literature (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) by Bozzetti and Bozzetti [26 & ] also showed that a higher quantity of parenteral amino acids than usually administered via parenteral feeding might be useful to cancer patients as whole body protein synthesis remained high even at an amino acid intake of 1.8-2.0 g amino acid/kg/day, whereas whole body protein breakdown was unchanged or decreased. This indicates that the intravenous dosage of essential amino acids/kg/day should be increased in cancer to at least 1.2 g/kg/day. These data are in line with the recent study by Winter et al. [13] showing that hyperaminoacidemia because of intravenous administration of amino acids is able to activate a normal protein anabolic response in cachectic NSCLC patients.
Anticancer treatment: a new area of interest in cancer is the effect of anticancer treatment on protein metabolism and the anabolic response to feeding. Animal studies recently showed that chemotherapeutic agents contribute to muscle and fat wasting by altering lipid metabolism, inducing a rapid inflammatory response, suppressing food intake, and inducing genes involved with the ubiquitin proteasome and autophagy lysosome systems [27, 28] . In advanced NSCLC [11 & ], we showed that the anabolic response to amino acids in cancer was not affected by previous chemotherapy. In line, oral commercial nutritional supplementation in 92 patients with advanced NSCLC undergoing paclitaxel and cisplatin/carboplatin treatment [29] resulted in a greater energy and protein intake and muscle gain, and lower values for fatigue, loss of appetite, and neuropathy than in the control group who received an isocaloric diet. A positive effect of oral nutritional intervention on body weight and muscle mass during chemotherapy or concurrent chemoradiotherapy in cancer was also observed by us and others in the past years [29] [30] [31] [32] [33] [34] [35] [36] ( Table 2 ). Some evidence exists that surgery does not hamper the anabolic response to feeding in cancer as shown by the improved leucine balance to a commercial amino acid infusion in cancer patients within 48 h of undergoing colorectal surgery [37] . The patient's presurgery catabolic state and age were significant determinants of the anabolic effects of the feeding regimen with more catabolic and younger patients showing the greatest benefit. In line, colorectal cancer patients undergoing surgical resection [21] showed normalization of the observed presurgery catabolic changes in protein metabolism 6 weeks after surgery. The recovery in postprandial muscle protein synthesis after surgery was inversely related to the degree of muscle atrophy. The above mentioned studies suggest that the anabolic potential remains exploitable in cancer patients even shortly after undergoing chemotherapy or surgery.
Aging: In our ageing society, cancer patients are older than in the past. As aging is associated with increased splanchnic extraction, a lower response to ingested proteins and alterations in human muscle protein metabolism, older adults need more dietary protein than younger adults to maintain good health and functionality [38, 39] . In older cancer patients, the combination of age-related decline of muscle mass (sarcopenia) and the presence of cancer (and related cachexia) could hamper the anabolic response to feeding. Although a lower anabolic response of the skeletal muscle to amino acids was found in older cancer patients than in healthy older controls, older cancer patients were still responsive to amino acids [40] .
FUTURE PERSPECTIVES
There is recent evidence that a (genetic) component exists in cachexia among cancer patients [41] , although this was not found for cancer-related appetite loss [42] . Furthermore, factors like individual body composition and metabolic phenotype may also play a role in the development of cachexia in cancer. Interindividual differences in metabolic phenotype among cancer patients might be present in substrate levels and intermediary products of proteins (metabolomics), kinetics through related pathways (fluxomics), and/or digestion and absorption of food components. Identification of the metabolic kinetic phenotype possibly can predict cachexia and related outcome in cancer patients and thus could lead to individualized therapeutic approaches to prevent cachexia, thereby improving quality of life, well-being, and clinical and overall outcome in cancer.
Although it is generally accepted that the protein needs of cancer patients are elevated, the existing international guidelines on the optimal dose of protein and amino acid intake in cancer are vague. Recent studies indicate that further fine-tuning of nutritional care is required in cancer which might involve compounding of nutritional formulations containing high levels of essential amino acids. Insight in the optimal protein and amino acid requirements on an individual basis is needed to further improve and personalize nutritional care in patients with cancer.
CONCLUSION
Recent studies indicate that advanced cancer patients are able to obtain a normal protein anabolic response to high-quality proteins or parenteral feeding that contain a high amount of essential amino acids. The studied cancer patients, however, were often characterized by a normal body weight or even obesity, which follows the trend in the general population, and mild systemic inflammation. There is also some evidence that even in more severe catabolic conditions, such as chemotherapy, the anabolic potential of cancer patients remains exploitable although more studies are needed to confirm this. To be sure that there is not a potential selection bias in the published research studies, more research needs to be initiated examining the anabolic potential of very weak cancer patients with a short life expectancy (<3 months) and in those with high levels of systemic inflammation.
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